Engerix-b 20 MCG/ML syrnml
Ended Awarded Last action
- Contract number
- SPE2D326F3176
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $5,909
Award facts
- Contract value 100% obligated
- $5,908.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a $5,908.50 firm fixed-price delivery order for ENGERIX-B 20 MCG/ML syringes on January 5, 2026, with a completion date of January 6, 2026. The contract carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Medical Supply Chain division, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC, valued at $499,999,999 and extending through December 31, 2036, positions DMS Pharmaceutical Group as a critical regional pharmaceutical supplier supporting Department of Defense military healthcare operations worldwide.
ENGERIX-B is a hepatitis B vaccine distributed through this delivery order to support ongoing medical supply needs of federal military healthcare facilities. The Defense Logistics Agency's PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to ensure reliable access to comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, and medical consumables across the military health system. DMS Pharmaceutical Group's demonstrated performance across diverse product categories and numerous prior delivery orders validates its capability to fulfill specialized pharmaceutical requirements essential to Department of Defense operations. The contract includes no identified subcontractors, with DMS Pharmaceutical Group serving as the sole prime contractor responsible for vaccine distribution and fulfillment.
Quick answers
Who was awarded contract SPE2D326F3176?
SPE2D326F3176 was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on January 5, 2026.
How much is contract SPE2D326F3176 worth?
The government has obligated $5,909 on SPE2D326F3176.
Is contract SPE2D326F3176 an order under another contract?
Yes. SPE2D326F3176 is a delivery order under SPE2D021DA002, an indefinite delivery contract.
Was contract SPE2D326F3176 competed?
The extent of competition for SPE2D326F3176 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award